Novo Nordisk's Latest Cease-and-Desist Wave: Which Compounders Got Named

Novo Nordisk's legal team has been busy. Following the end of the FDA shortage designation for semaglutide and the closed 503B comment period, the company has sent cease-and-desist notices, filed suits, and pressed telehealth marketers on trademark and off-label promotion claims. Here's how to read the litigation without falling for panic marketing.

The Legal Theories Being Used

Novo's actions don't rest on a single theory. The most common are trademark infringement (using "Wegovy" or "Ozempic" as marketing terms for compounded semaglutide), false advertising (claiming compounded product is "the same as" the brand), and unfair competition (implying pharmacy-manufactured product without proper distinction). Some suits also raise off-label promotion arguments where compounders marketed semaglutide for indications the brand isn't approved for.

Note what the suits generally don't argue: they typically don't claim that all compounded semaglutide is illegal. They target specific marketing practices and specific compounders. That distinction matters for how patients interpret the news.

Categories of Named Parties

Named parties tend to fall into three buckets. First, telehealth marketing companies that used Novo's brand names in ads or landing pages. Second, compounding pharmacies that sold products marketed with brand comparisons or "identical to Wegovy" language. Third, service providers (payment processors, ad networks) that facilitated the above.

Names have been public in filings, but Novo's list evolves month to month. Rather than tracking individual defendants, patients should focus on how the compounder they're using markets its own product. If your compounder's landing page prominently uses "Wegovy" or "Ozempic" as a marketing hook, that's a signal to expect potential disruption.

What Patients Have Experienced

Downstream, patients on affected platforms have reported three patterns: sudden marketing changes (compounder rebrands and drops Novo references), platform switches (fulfillment moves to a different pharmacy mid-treatment), and in the worst cases, program shutdowns with limited notice. Refund handling has been mixed, and the pharmacies that provide clear continuity paths are the ones patients recommend to each other.

Litigation Signal vs Noise

Not every cease-and-desist is a shutdown notice. Many are opening negotiation letters that resolve with marketing changes and no operational impact on patients. Others end with settlements that include continued shipping under new marketing terms. The ones to worry about are named-defendant lawsuits with injunctive relief requested — those can halt operations while the case proceeds.

If you're on a platform that receives a cease-and-desist, the platform typically has 10–30 days to respond. During that window, patient service usually continues. Use that window to establish a backup pharmacy relationship — not to panic-buy or hoard.

The Brand-Name Angle

Novo's litigation strategy has a commercial logic: pushing patients back toward Wegovy at NovoCare's newly-lowered cash rates. For patients whose compounded price is under $250/month, the brand path isn't yet competitive. For patients paying $299–$399 for compounded, the NovoCare $349 rate is essentially at parity — and switching may be simpler than fighting through compounder disruption.

Where to Start